The present invention provides engineered proline hydroxylase polypeptides for the production of hydroxylated compounds, polynucleotides encoding the engineered proline hydroxylases, host cells capable of expressing the engineered proline hydroxylases, and methods of using the engineered proline hydroxylases to prepare compounds useful in the production of active pharmaceutical agents.

The disclosure herein provides a fusion protein comprising prolyl 4-hydroxylase alpha subunit (P4HA) and a soluble protein partner. A fusion protein comprising prolyl 4-hydroxylase alpha subunit (P4HA1) and prolyl 4-hydroxylase beta subunit (P4HB) is provided. A microorganism including a fusion protein comprising prolyl 4-hydroxylase alpha subunit-1 (P4HA1) and prolyl 4-hydroxylase beta subunit (P4HB) is provided. The disclosure provides a microorganism including a fusion protein comprising prolyl 4-hydroxylase alpha subunit-1 (P4HA1) and prolyl 4-hydroxylase beta subunit (P4HB); and another protein to be hydroxylated. A method for providing skincare benefits including applying the fusion protein of the present disclosure on skin is also taught.

The present disclosure provides engineered proline hydroxylase polypeptides for the production of hydroxylated compounds, polynucleotides encoding the engineered proline hydroxylases, host cells capable of expressing the engineered proline hydroxylases, and methods of using the engineered proline hydroxylases to prepare compounds useful in the production of active pharmaceutical agents.

The present invention provides engineered proline hydroxylase polypeptides for the production of hydroxylated compounds, polynucleotides encoding the engineered proline hydroxylases, host cells capable of expressing the engineered proline hydroxylases, and methods of using the engineered proline hydroxylases to prepare compounds useful in the production of active pharmaceutical agents.

Compositions comprising butyric acid and derivatives thereof for a method of treating intestinal disease. These compositions act to stabilize HIF through the inhibition of PHDs.

The present invention provides engineered proline hydroxylase polypeptides for the production of hydroxylated compounds, polynucleotides encoding the engineered proline hydroxylases, host cells capable of expressing the engineered proline hydroxylases, and methods of using the engineered proline hydroxylases to prepare compounds useful in the production of active pharmaceutical agents.

The invention described herein relates to a novel non-naturally occurring, elastomeric animal-free recombinant fusion biopolymers produced in plants through transient expression. More specifically, the present invention describes polynucleotides encoding fusion proteins of a non-human scleroprotein with a human collagen, wherein said fusion protein is capable of forming hydroxylated triple helix fibers. In particular fusion proteins of a Spidroin like protein with a human collagen. More in particular, eithera Spidroin-I/Collagen Type-I fusion protein, capable of forming hydroxylated triple helix fibers, or a Fibroin-III/Collagen Type-I fusion protein, capable of forming hydroxylated triple helix fibers. The present invention has improved properties (e.g., thermostability, young's modulus, cell adhesion, degradability, and the like) versus that of native Collagen Type-I. Also described are methods for use thereof, such as the use of electrospun scaffolds which are particularly well suited for biomedical or cosmetic applications as defined in the claims.

The present invention provides engineered proline hydroxylase polypeptides for the production of hydroxylated compounds, polynucleotides encoding the engineered proline hydroxylases, host cells capable of expressing the engineered proline hydroxylases, and methods of using the engineered proline hydroxylases to prepare compounds useful in the production of active pharmaceutical agents.